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Outcomes of percutaneous endovascular
intervention for type II endoleak with aneurysm
expansion
Abdulhameed Aziz, MD,a Christine O. Menias, MD,b Luis A. Sanchez, MD,a Daniel Picus, MD,c
Nael Saad, MD,c Brian G. Rubin, MD,a John A. Curci, MD,a and Patrick J. Geraghty, MD,a St. Louis, Mo
Objective: Type II endoleak (T2EL) with aneurysm expansion is believed to place patients at risk for aneurysm-related
mortality (ARM). Treatment with glue and/or coil embolization of the aneurysm sac, inferior mesenteric artery (IMA),
and lumbar branches via translumbar or transarterial approaches has been utilized to ablate such endoleaks, and thus
decrease ARM. We evaluated the midterm results of percutaneous endovascular treatment of T2EL with aneurysm
expansion.
Methods: Single-institution, 5-year (January 2003 to August 2008) retrospective study of all endovascular interventions
for T2EL with sac expansion. Blinded, independent review of all available pre- and post-T2EL intervention computed
tomography (CT) scans was performed. Aneurysm sac maximal transverse diameters and aneurysm sac growth rates prior
to and following T2EL intervention were analyzed.
Results: Forty-two patients (34 male, eight female; mean age, 75) underwent T2EL intervention at 26 20 months after
endovascular aneurysm repair (EVAR) and were subsequently followed for 23  20 months. Seven out of 42 patients
(17%) underwent repeat T2EL intervention. Interventions included 44 translumbar sac embolizations, and transcatheter
embolizations of nine IMAs and seven lumbar/hypogastric arteries. Aneurysm diameter was 6.1  1.6 cm at EVAR,
6.6  1.5 cm at initial T2EL treatment, and 6.9  1.7 cm at last follow-up. There were no significant differences in the
rates of aneurysm sac growth pre- and post-T2EL treatment. At last follow-up imaging, recurrent or persistent T2ELwas
noted in 72% of patients. Of 42 patients, nine (21%) received operative endoluminal correction of occult type I or type III
endoleaks that were diagnosed during the T2EL angiographic intervention. There were no aneurysm ruptures or ARMs
during follow-up; overall mortality for the 5-year study period was 24%.
Conclusions: In this series, percutaneous endovascular intervention for type II endoleak with aneurysm sac growth does not
appear to alter the rate of aneurysm sac growth, and the majority of patients display persistent/recurrent endoleak. However,
diagnostic angiographic evaluation may reveal unexpected type I and III endoleaks and is therefore recommended for all
patients with T2EL and sac growth. While coil and glue embolization of aneurysm sac and selected branch vessels does not
appear to yield benefit in our series, the diagnosis and subsequent definitive treatment of previously occult type I and III
endoleaks may explain the absence of delayed rupture and ARM in our series. (J Vasc Surg 2012;55:1263-7.)
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mEndovascular aneurysm repair (EVAR) has become
established as an alternative to open abdominal aortic an-
eurysm repair over the past 2 decades.1,2 The early advan-
tages in morbidity and mortality conferred by EVAR are
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doi:10.1016/j.jvs.2011.10.131ubstantially offset by the need for serial endograft surveil-
ance and frequent reinterventions.2-5 There is little debate
egarding the merit of prompt treatment of type I and III
ndoleaks. The necessity, optimal timing, and most effica-
ious type of secondary intervention for type II endoleak
T2EL) have generated greater controversy, although it is
idely accepted that intervention is unnecessary if the
neurysm sac size remains stable or diminishes.6-8
As the natural history of T2EL is not fully understood,
roposed treatment algorithms are in part based upon
necdotal experience9 or outcomes of retrospective studies
valuating all patients diagnosed with T2EL, rather than
hose patients with accompanying sac enlargement.6-8,10
pecifically, these reports promote the selective use of
ngiographic modalities to treat T2EL but do not detail
id- and long-term outcomes of these interventions. Such
nformation is necessary to define whether these treatments
ffer complete or partial success in halting aneurysm sac
rowth and preventing rupture. As our institution followed
routine policy of percutaneous endovascular intervention
or all T2ELs associated with aneurysm sac growth of 5
m, the purpose of this study was to specifically evaluate
esults of our 5-year experience with this technique.
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A 5-year (January 2003 to August 2008) retrospective
study of all patients treated for aneurysm enlargement
associated with T2EL was performed within the Barnes-
Jewish Care Network. This study was conducted in accor-
dance with the approval of the Institutional Review Board
of Washington University Medical School. Patient demo-
graphics, including concurrent illnesses, medications, radio-
logic follow-up, and treatment modalities, were catalogued in
a database created via Microsoft Access (Microsoft Inc, Red-
mond, Wash).
All obtainable follow-up imaging reports after initial
EVAR were recorded, and all available radiographic images
were compiled. Fifty-nine percent of pre-T2EL interven-
tion images from referring institutions were not available
for review due to Institutional Review Board-related con-
straints. In those instances, the written imaging reports
were used to document the presence of endoleak and the
size of the abdominal aortic aneurysm (AAA) sac. Ninety-
one percent of post-T2EL intervention images were avail-
able for review, including 137 computed tomography (CT)
scans and two abdominal ultrasounds, as almost all patients
were followed at our institution after these interventions.
To standardize our image review, all available images (both
pre- and post-T2EL intervention) were independently re-
viewed by an abdominal imaging radiologist who was
blinded to the initial reported findings of the studies. The
independent radiologist reviewer documented the AAA sac
size, presence of endoleak, and type of endoleak.
Deaths were recorded by reviewing hospital records
and by interrogating the Social Security Death Index
(SSDI). The follow-up period was defined as the time from
initial EVAR to the most recent imaging study. Closeout of
the study was February 2009, allotting at least 6 months of
follow-up from the last T2EL treatment recorded in this
study.
In addition to calculating the absolute changes in AAA
sac size, we also analyzed whether percutaneous endovas-
cular intervention favorably altered the rate of growth of
the sac. “Slope” values represent the regression line calcu-
lated by plotting aneurysm sac size against time. Two time
periods were compared: the interval between EVAR and
initial intervention for T2EL, and the interval between initial
intervention for T2EL and last documented follow-up im-
aging. A minimum of two imaging studies within each time
interval were required to generate a slope value. The equa-
tion for the slope of the regression line is:
b
 (x x)(y y)
 (x x)2
Slope values prior to and following T2EL intervention
were compared using the Mann-Whitney t-test.
Statistical analysis was performed using the statistical
software package InStat (GraphPad Software Inc, La Jolla,
Calif) and Microsoft Excel (2003) (Microsoft Inc). gESULTS
Forty-two consecutive patients were identified as having
ndergone angiographic intervention for T2EL with aneu-
ysm sac expansion. The average age of the patient was 75
range, 52-89). Patient demographics and medical comor-
idities are classified in Table I. At the time of T2EL interven-
ion, mean aneurysm sac diameter was 6.5 cm (range, 4.0-
0.6 cm). The approaches used for diagnostic angiography
re detailed in Table II. Percutaneous endovascular interven-
ions, inclusive of repeat treatments, comprised 44 translum-
ar embolizations, seven transcatheter embolizations of lum-
ar or hypogastric vessels, and nine inferior mesenteric artery
mbolizations. Seven out of 42 patients (17%) required a
epeat percutaneousT2EL intervention after initial treatment,
hile nine out of 42 patients (21%) required subsequent redo
emoral cut-down and placement of additional endografts to
epair type I or III endoleaks. There were no instances of
neurysm rupture or aneurysm-related mortality. Overall
ortality rate in the 5 years of follow-up from study initiation
as 24% (10 of 42 patients).
Incidence of type 2 endoleak accompanied by sac
rowth. We could not obtain the total number of EVARs
erformed at the referring institutions during the study
eriod and therefore cannot provide a global denominator
o assess the incidence of T2EL accompanied by sac
able I. Demographics and comorbidities
Demographic/comorbidity Percentage of patients
emale 19
ypertension 86
oronary artery disease 60
iabetes mellitus 17
OPD/home O2 use 12
RI (creatinine 2) 5
SRD 0
ctive smoking 14
F 40% 0
AD/cerebrovascular disease 24
ymptomatic AAA at EVAR 7
uptured AAA at EVAR 5
AA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
isease; CRI, chronic renal insufficiency; EF, ejection fraction; ESRD,
nd-stage renal disease; EVAR, endovascular aneurysm repair; PAD, periph-
ral arterial disease.
able II. Initial angiographic approach to type II
ndoleak
Angiographic approach Number of patients (%)
ransabdominal 1 (2)
ransaxillary 1 (2)
ransfemoral 10 (24)
ransfemoral, then translumbar 13 (31)
ranslumbar 16 (38)
ranslumbar, then transfemoral 1 (2)
otal 42 (100)rowth. However, 16 of the 42 patients underwent initial
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Volume 55, Number 5 Aziz et al 1265EVAR at our institution, and we performed 712 total
EVARs over the study period. Thus, our institutional inci-
dence of T2EL with sac growth was 2.2%.
Maximal aneurysm diameter. Changes in maximal
aneurysm diameter are noted in Fig 1. Aneurysm diameter
was 6.1 1.6 cm at EVAR, with growth to 6.6 1.5 cm at
time of initial T2EL treatment. After percutaneous endo-
vascular intervention for T2EL, there was continued
growth to 6.9  1.7 cm at last follow-up. At a mean
follow-up of 48 months (from initial EVAR to last follow-
up), the increase in aneurysm size was statistically signifi-
cant (6.1  1.6 cm to 6.9  1.2 cm, P  .05).
Aneurysm growth rates. There was no significant dif-
ference in pre- and post-T2EL treatment growth rates (Fig 2,
A). When we excluded those patients who underwent opera-
tive endovascular correctionof occult type I and III endoleaks,
there was also no change in growth rate (Fig 2, B).
Endoleak persistence and recurrence. The incidence of
persistent or recurrent endoleak at last follow-up is shown in
Fig 3. Interpretation of CT findings after sac embolization
with radio-opaque materials can be challenging; therefore, all
available postembolization scans were reviewed by an inde-
pendent, blinded abdominal imaging radiologist, with docu-
mentation of endoleaks and aneurysm sac diameter. Arterial-
and delayed-phase imaging are utilized in our post-EVARCT
angiography protocol; the delayed images were noted to be
more efficacious for detection of endoleaks. At last follow-up,
72% of patients (per independent image review) had docu-
mentation of persistent or recurrent T2EL.
Diagnosis and treatment of type I and III endoleaks.
Nine of 42 patients (21% of the cohort) ultimately received
operative intervention after initial diagnosis of a T2EL. In
each of these patients, operative endovascular intervention
was undertaken after angiography demonstrated previously
occult type I or III endoleaks. Collectively, there were five
repairs for type I endoleak and four repairs for type III
endoleak performed. Despite successful treatment of the
type I and III endoleaks, seven of these nine patients (78%)
continued to display continued sac growth in follow-up.
Embolization modality. The most frequent method of
embolization was translumbar introduction of coils and/or
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Fig 1. Abdominal aortic aneurysm (AAA) diameter changes over
time. *P  .05 for AAA size at last follow-up vs initial AAA size.
Error bars  one standard deviation. T2EL, Type II endoleak.glue to the aneurysm sac. A minority of patients received pransarterial coil embolization of branch vessels, either with or
ithout translumbar sac embolization. The mode of emboli-
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ig 2. A, Aneurysm growth rate stratified before and after initial
ype II endoleak (T2EL) percutaneous endovascular intervention
or all patients. B, Aneurysm growth rate stratified before and after
nitial T2EL percutaneous endovascular intervention, excluding
hose patients who received operative endoluminal correction of
ype I and III endoleaks. AAA, Abdominal aortic aneurysm;
VAR, endovascular aneurysm repair.
Type I
2%
NO
26%
YES
72%
ig 3. Patients with type II endoleak (T2EL) at latest
ollow-up.atients that received transarterial coil embolization.
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May 20121266 Aziz et alProcedural complications. There were no deaths re-
lated to percutaneous endovascular intervention for T2EL. A
solitary instance of contrast nephropathy (2.4%) was noted,
with spontaneous recovery and no need for hemodialysis.
DISCUSSION
Despite reports promulgating the importance of treating
type II endoleak,7,11,12 thenatural historyof these phenomena is
not fullydefined.The literature is repletewithmultiple suggested
routes of T2EL ablation, including laparoscopic ligation of the
inferiormesenteric artery,13 concurrent operative lumbar embo-
lization,14,15 post-EVAR embolizations,16,17 and post-EVAR
operative approaches.18 Previously, our institutional experience
has shown that continued observation of persistent T2EL with
stable aneurysmsac size isboth safe andcost-effective.6 In lightof
this priorwork,we believe continued aneurysm sac growth to be
of greater concern than the continuous or intermittent docu-
mentation of sac perfusion and view aneurysm diameter stabili-
zation or shrinkage as the sine qua non of successful endoleak
intervention.
In this report, we catalogue the outcomes of percutaneous
endovascular intervention in 42 patients who presented with
T2EL accompanied by aneurysm enlargement. Translumbar sac
embolization and transarterial branch vessel embolization were
the most frequently used modalities for T2EL treatment. We
found that the rate of aneurysm growth in these patients is slow
(10% total aneurysm diameter increase per year), but does not
appreciably diminish after one or more interventions for T2EL.
Despite single or repeated percutaneous endovascular interven-
tion, sac size continued to gradually increase. Finally, blinded
assessment by an expert abdominal radiologist confirmed that
over two-thirds of patients had persistent or recurrent T2EL at
completion of the study period.
By most measures, the outcomes of percutaneous en-
dovascular treatments for T2EL with aneurysm growth in
this study were disappointing. Indeed, the one finding that
may have positively impacted patient outcomes, and sal-
vaged the role of angiographic interventions for this con-
dition, was the unexpected diagnosis of type I and III
endoleaks in a substantial minority (21%) of patients. A
strong argument can be made that the subsequent defini-
tive treatment of these occult type I and III endoleaks may
have contributed to the absence of aneurysm rupture and
aneurysm-related mortality in our patient cohort.
Even if we recognize value in the diagnosis of previously
occult seal zone failures, the optimal management of the
remaining patients with T2EL and aneurysm sac expansion
remains unclear. Unfortunately, recent reports do not show
any substantial mid- or long-term follow-up for patients who
are treated using similar angiographic embolization tech-
niques.6-8,10 Even when used during initial EVAR14 or with
follow-up via innovative ultrasound techniques,17,19 results
are not available beyond 2 years. Hypertension is prevalent in
our patient cohort and has been identified as a preoperative
T2EL risk factor in the population treated with the Zenith
graft (Cook Medical Inc, Bloomington, Ind).20 Aggressive
medical control of hypertension is strongly recommended for
this patient cohort. Prospective data collection from multiple Snstitutions with substantial EVAR cohorts will be necessary
o provide a stronger evidence base for the management of
hese challenging patients. As concern has grown regarding
he cumulative doses of radiation incurred byCT angiography
ollow-up to 5 years and beyond, alternative means of surveil-
ance have been sought, including magnetic resonance an-
iography and contrast-enhanced ultrasound.21 In our prac-
ice, stable and shrinking aneurysms are often monitored by
ransabdominal ultrasound,withCTangiography reserved for
he evaluation of new sac growth or other concerning find-
ngs.
We recognize several significant limitations to this study.
t is limitedby its retrospective naturewith according selection
ias and without control for timing or type of T2EL treat-
ent. As noted in the Methods section, the majority of
re-T2EL intervention images were not available for direct
eview, although the greatmajority of critical postintervention
ollow-up images were able to be directly reviewed. Percuta-
eous endovascular interventionswere conductedby a solitary
xpert interventional radiologist at a single institution; multi-
enter data would strengthen the generalizability of our find-
ngs. The translumbar route was the predominant approach
tilized, with a minority of transfemoral approaches. In each
nstance, our interventional radiologist pursued all promising
outes until angiographic success had been achieved. The
ossibility remains that other approaches to endoleak abla-
ion, including aggressive laparoscopic clipping of all sac
ranches or multivessel transarterial embolization, might bet-
er mitigate perigraft flow, but convincing long-term out-
omes data for such approaches are lacking. Several types of
rafts were used, and the study was insufficiently powered to
dequately assess aneurysm growth trends between these dif-
erent graft types. Gaps in initial medical history and changing
edications made it impossible to track the potential effect of
ypertension and anticoagulant/antiplatelet medications in
hese patients. Despite review of availablemedical records and
he SSDI, some patients expired without known cause, and
ccult aneurysm-related mortality remains a potential etiol-
gy.
In summary, our data question the efficacy of percuta-
eous endovascular interventions for T2EL accompanied
y aneurysm sac growth. We recommend dedicated angio-
raphic evaluation of these patients, with prompt treatment
f occult type I and III endoleaks. Further study is required
o define if any subset of patients with T2EL and aneurysm
rowth would benefit from targeted percutaneous endo-
ascular intervention, or other modes of endoleak ablation.
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This article questions our current assumptions concerning the
treatment outcomes of type II endoleaks. While it is generally
acknowledged that these leaks occur frequently and are usually
merely annoying, the results of treating more pernicious type II
endoleaks that are accompanied by sac enlargement are largely
unknown. These latter leaks, while rare, are often complicated,
involving several sets of lumbar arteries, the inferior mesenteric
artery, and extensive collateral networks. It is not surprising that
simple embolization of the lumber, mesenteric, or internal iliac
branches would not control these leaks. In fact, several groups have
pointed this out, recommending translumbar approaches with
coils and glue, and insisting on complete obliteration of the leak
“nidus” within the sac.
Until now, many of us probably thought that this direct sac
approach would be definitive and long-lasting. This article
questions that assumption by indicating that 72% of patients
who underwent treatment had not only persistent leaks, but
more important, continuing sac growth. But probably the au-
thors’ most important point is that the aneurysms of somengiography on all patients with any type of leak and an enlarg-
ng aneurysm. This advice is reasonable and widely accepted.
The authors recognize several weaknesses in their evaluation
f their data. The most glaring is the inability of the authors to
valuate almost 60% of the preoperative computed tomography
cans, relying on the initial radiologic report, a practice fraught
ith inaccuracies. While this damages the calculations of the pre-
perative slope value, it does not change the fact that the leaks
ersisted or recurred despite treatment. In addition, the reader has
o accept the complete abolition of the endoleak since no images
ere provided. Furthermore, the interventional radiologist who
erformed the procedures favored translumbar sac embolization
ver other modalities.
As any good article should, the report raises questions: Should
here be a size threshold reached before treatment of type II leaks?
oes sac enlargement of 5 mm in a 5-cm aneurysm have the same
rognosis as 5 mm growth in an 8-cm aneurysm? Should we perform
ngiography on patients with a long infrarenal neck, small aneurysm,
nd 5-mm sac increase? What is the best method for imaging and
reating these leaks? Hopefully, this article will stimulate other groups
o look at their data and help answer these questions.
